CN105231462B - Compound antihypelipidemic nutrient powder - Google Patents
Compound antihypelipidemic nutrient powder Download PDFInfo
- Publication number
- CN105231462B CN105231462B CN201510802757.7A CN201510802757A CN105231462B CN 105231462 B CN105231462 B CN 105231462B CN 201510802757 A CN201510802757 A CN 201510802757A CN 105231462 B CN105231462 B CN 105231462B
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- nutrient powder
- compound antihypelipidemic
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 30
- 150000001875 compounds Chemical class 0.000 title claims abstract description 12
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 11
- 235000018102 proteins Nutrition 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 8
- 241000209140 Triticum Species 0.000 claims abstract description 8
- 235000021307 Triticum Nutrition 0.000 claims abstract description 8
- 235000004279 alanine Nutrition 0.000 claims abstract description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 7
- 239000005862 Whey Substances 0.000 claims abstract description 7
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 7
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 7
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 240000008892 Helianthus tuberosus Species 0.000 claims abstract description 6
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims abstract description 6
- 240000006240 Linum usitatissimum Species 0.000 claims abstract description 6
- 235000004431 Linum usitatissimum Nutrition 0.000 claims abstract description 6
- 235000004426 flaxseed Nutrition 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000012054 meals Nutrition 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 235000008729 phenylalanine Nutrition 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 230000003914 insulin secretion Effects 0.000 abstract description 8
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 7
- 235000000346 sugar Nutrition 0.000 abstract description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 7
- 230000000291 postprandial effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 7
- 102000051325 Glucagon Human genes 0.000 description 7
- 108060003199 Glucagon Proteins 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 101710176384 Peptide 1 Proteins 0.000 description 7
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 7
- 229960004666 glucagon Drugs 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002304 glucoses Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- -1 unsaturated fatty acid leukotrienes Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A kind of compound antihypelipidemic nutrient powder, in terms of parts by weight, it is made up of following composition：20 80 parts of PURE WHEY, 20 80 parts of hydrolyzed wheat protein matter, 15 parts of phenylalanine, 15 parts of alanine, 10 40 parts of linseed meal, 5 15 parts of egg yolk lecithin, 1 10 parts of jerusalem artichoke powder.Compound antihypelipidemic nutrient powder of the present invention can promote insulin secretion, reduce insulin resistance, reduce postprandial blood sugar.
Description
Technical field
The invention belongs to health product technology field, and in particular to a kind of compound antihypelipidemic nutrient powder.
Background technology
Diabetes B pathogenesis:A insulin resistances；B hypoinsulinisms.Treatment means mainly rely at present
Medicine improves blood insulin amount to reduce blood glucose, and existing treatment method deposits problem both ways:(1) lifelong medication；(2) it is long-term
Medication produces drug resistance.
Scientific research is found, the one kind of human body alimentary canal L cells as Endocrine Cells In The Gut, secretes glucagon
Peptide -1（GLP-1）, GLP-1 can stimulate islet β cell insulin and suppress α cells secrete glucagons, have
The effect of good reduction postprandial blood sugar.GLP-1 may additionally facilitate propagation and the regeneration of β cells, prevent β Apoptosis.GLP-1 oneself
As thoroughly defeating the Main way of diabetes；At present, carry out numerous studies in the field, and there is new drug application to face
Bed (Liraglutide etc.), but this kind of medicine has more side effect (50%), also fails to large-scale popularization at present.
Thus it is necessary to develop a kind of food, equally can also excites alimentary canal L cells secrete glucagon samples peptide -1
（GLP-1）, and be free from side effects.
The content of the invention
An object of the present invention is to provide a kind of compound antihypelipidemic nutrient powder, can promote to secrete GLP-1, reach hypoglycemic
Recover with promotion islet function, insulin secretion can be promoted, reduce postprandial blood sugar, nutritional ingredient is comprehensive, in good taste, green peace
Entirely.
The second object of the present invention is the preparation method for providing the compound antihypelipidemic albumen powder.
Present invention research is found：(1) some amino acid can excite enteron aisle L cells secrete glucagon samples peptide -1（GLP-
1）, alanine, glutamine, leucine effect is substantially；(2) chain and long-chain free fatty acids excite enteron aisle L cells to secrete pancreas in
Glucagon-like peptide -1（GLP-1）Effect is stronger；(3) leucine directly facilitates Islet Cells Insulin secretion effect in amino acid
Most strong, glutamine can significantly improve leucine and directly facilitate Islet Cells Insulin secretion effect；(4) lactalbumin can reduce
Insulin resistance.
Multiple medical experiments prove
a:Lactalbumin contains abundant branched-chain amino acid, and particularly leucine content enriches, and leucine can excite enteron aisle L
Cells secrete glucagon sample peptide -1（GLP-1）, while also there is the function of directly facilitating insulin secretion.PURE WHEY
Mixing carbohydrate is edible can also to reduce insulin resistance.
b:Hydrolyzed wheat protein matter is with aleuronat（Gluten）For raw material, using a variety of enzyme preparations, by fixed
To digestion and the specific spray-dried acquisition of small peptide isolation technics, hydrolyzed wheat protein matter is containing abundant glutamine, glutamy
Amine, which has, strengthens leucine rush enteron aisle L cells secrete glucagon samples peptide -1（GLP-1）Effect.
c：Alanine and phenylalanine have relatively excites by force enteron aisle L cells secrete glucagon samples peptide -1 by force（GLP-1）
Effect.
d：The lecithin that long-chain unsaturated fatty acid leukotrienes and yolk of the linseed containing richness are rich in has stronger excite
Enteron aisle L cells secrete glucagon samples peptide -1（GLP-1）Effect;Leukotrienes and lecithin have regulation blood fat simultaneously, and blood glues
Effect, it is long-term use of to have remarkable effect to prevention diabetic complication.
e：It is obvious to improve blood pressure and blood lipoid effect containing abundant dietary fiber for jerusalem artichoke powder.
Compound antihypelipidemic nutrient powder of the present invention, in terms of parts by weight, it is made up of following composition：
PURE WHEY 20-80 parts, hydrolyzed wheat protein matter 20-80 parts, phenylalanine 1-5 parts, alanine 1-5 parts are sub-
Numb seed powder 10-40 parts, egg yolk lecithin 5-15 parts, jerusalem artichoke powder 1-10 parts.
Wherein preferred 20-40 parts of PURE WHEY, hydrolyzed wheat protein is of fine quality to select 20-40 parts, the preferred 3-5 of phenylalanine
Part, the preferred 3-5 parts of alanine, the preferred 20-30 parts of linseed meal, the preferred 9-15 parts of egg yolk lecithin, the preferred 5-10 parts of jerusalem artichoke powder.
The preparation method of compound antihypelipidemic nutrient powder of the present invention is as follows：
By PURE WHEY, hydrolyzed wheat protein matter, phenylalanine, alanine, egg yolk lecithin, linseed meal, chrysanthemum
Taro powder mixes in proportion, sterilization packaging.
Hypoglycemic food composition of the present invention has the characteristics that:
(1) promote L cells to make secretion GLP-1, reach hypoglycemic and promote islet function to recover；
(2) promote insulin secretion, reduce insulin resistance, reduce postprandial blood sugar；
(3) nutritional ingredient is comprehensive, in good taste；
(4) it is green safe.
The instructions of taking and dose of compound antihypelipidemic nutrient powder of the present invention are as follows：10-20 grams/times, 3 times a day, use 100-
The punching of 200ml boiling water is drunk.
Embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.
Table 1 is embodiment 1-6 and the formula of comparative example 1, and unit is gram.
Table 1
。
Table 2 is embodiment 7-12 and the formula of comparative example 2, and unit is gram.
Table 2
。
Experiment one：
Subject is 58 diabetics, in year at age (61 ± 0.4), is randomly divided into control group and test group, control group
Often eat staple food add 20 grams of general proteins powder (Amway), test group often eat staple food add 20 grams of hypoglycemic nutrition powders of embodiment 1, double blinding
Mode supplies, measurement 0,60,120min plasma glucoses and insulin concentration, after taking in egg mix white powder staple food, initial blood plasma
The concentration of glucose and insulin significantly raises, but after rise, blood glucose and pancreas islet caused by different mixed protein powder staple foods
Element reaction has significant difference；60,120min plasma glucose tests group and control group have after intake mixing hypoglycemic nutrition powder staple food
Notable difference (P<0.05).Insulin response is relatively taken in mixing general proteins powder staple food and is significantly increased, and increases by 101% He respectively
103%(P<0.05)。
Conclusion:Hypoglycemic nutrition powder and carbohydrate are taken in simultaneously can reduce postprandial blood sugar, caused insulin secretion accelerating
Effect is higher than intake general proteins powder and carbohydrate.
Experiment two：
Product embodiments 1-12 of the present invention, comparative example 1-2 and control group are subjected to clinical verification, test situation is as follows.
1st, object
The diabetic 150 of selection 30-60 year, nervous system positioning of the patient in group without obvious cerebrovas-cularaccident
Symptom, ordinary electrocardiogram inspection is without obvious myocardial ischemia or myocardial infarction, no High-grade Proteinuria and renal insufficiency, no proliferous type
PVR.
2nd, method
All patients are randomly divided into 15 groups according to medical order and sex, every group of 10 people, carry out diabetes propaganda and education, embodiment
1-12 and comparative example 1-2 groups patient often eat staple food add 20 grams of hypoglycemic nutrition powders, control group often eat staple food add 20 grams of common eggs
White powder (Amway), by diabetic diet management.
Measurement 0,60,120min plasma glucoses and insulin concentration.
3rd, result
(1) two group of pretherapy and post-treatment clinic of patient and laboratory data
Situations such as body weight, Bp, sugar before age between 15 groups, diabetic duration, men and women's ratio and experiment, fat, difference was without notable
Meaning (P ＞ 0.05), has comparativity, refers to table 3.
Clinic and laboratory data (x ± s) after 3 15 groups of patient's treatments of table
。
Table 3（Continued）
。
Insulin resistance refers to that a variety of causes makes insulin promote glucose uptake and the efficiency utilized to decline, and body is compensatory
Property hypersecretion insulin produce hyperinsulinemia, to maintain the stabilization of blood glucose.
Result of the test shows：The present invention can be obviously promoted insulin secretion, reduce insulin resistance, reduce postprandial blood sugar.
Claims (1)
1. a kind of compound antihypelipidemic nutrient powder, it is characterised in that in terms of parts by weight, be made up of following composition：PURE WHEY 30
Part, 40 parts of hydrolyzed wheat protein matter, 4 parts of phenylalanine, 4 parts of alanine, 20 parts of linseed meal, 12 parts of egg yolk lecithin, jerusalem artichoke
7 parts of powder；The preparation method of the compound antihypelipidemic nutrient powder, in turn includes the following steps：By PURE WHEY, wheat hydrolysis egg
White matter, phenylalanine, alanine, egg yolk lecithin, linseed meal, jerusalem artichoke powder mix in proportion, sterilization packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510802757.7A CN105231462B (en) | 2015-11-19 | 2015-11-19 | Compound antihypelipidemic nutrient powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510802757.7A CN105231462B (en) | 2015-11-19 | 2015-11-19 | Compound antihypelipidemic nutrient powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105231462A CN105231462A (en) | 2016-01-13 |
| CN105231462B true CN105231462B (en) | 2018-02-13 |
Family
ID=55029523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510802757.7A Active CN105231462B (en) | 2015-11-19 | 2015-11-19 | Compound antihypelipidemic nutrient powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105231462B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108142938A (en) * | 2018-01-31 | 2018-06-12 | 刘小辉 | Control special medicine purposes formula food meal replacement powder of blood glucose and preparation method thereof |
| CN109393490A (en) * | 2018-11-12 | 2019-03-01 | 厦门昶科生物工程有限公司 | The chromium-rich nutritious spirulina powder and preparation method of the extract containing natural flavone |
| CN110169580A (en) * | 2019-06-26 | 2019-08-27 | 重庆康泉健康管理有限公司 | Adjust metabolism, blood glucose, blood pressure, the comprehensive nutrition powder of blood lipid and preparation method thereof |
| CN114794487A (en) * | 2021-01-22 | 2022-07-29 | 中国科学院上海营养与健康研究所 | A method for treating diabetes |
| CN113826882A (en) * | 2021-02-21 | 2021-12-24 | 孙晓辉 | Dietary nutrition supplement for preventing and treating diabetes and preparation process thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102648752A (en) * | 2012-05-02 | 2012-08-29 | 中国食品发酵工业研究院 | Engineering rice suitable for people having unbalanced diet and with function of reducing blood glucose and preparation method of engineering rice |
| CN103431377A (en) * | 2013-07-17 | 2013-12-11 | 苟春虎 | Foodstuff capable of reducing blood pressure and preventing complications |
| CN103520281A (en) * | 2013-10-16 | 2014-01-22 | 江声 | Formula of biological agent for decreasing blood sugar |
-
2015
- 2015-11-19 CN CN201510802757.7A patent/CN105231462B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102648752A (en) * | 2012-05-02 | 2012-08-29 | 中国食品发酵工业研究院 | Engineering rice suitable for people having unbalanced diet and with function of reducing blood glucose and preparation method of engineering rice |
| CN103431377A (en) * | 2013-07-17 | 2013-12-11 | 苟春虎 | Foodstuff capable of reducing blood pressure and preventing complications |
| CN103520281A (en) * | 2013-10-16 | 2014-01-22 | 江声 | Formula of biological agent for decreasing blood sugar |
Non-Patent Citations (3)
| Title |
|---|
| 不同氨基酸对小鼠血糖影响的研究;王觐等;《军医进修学院学报》;20111130;第32卷(第11期);第1159页右栏第2段，第1160页左栏第1段 * |
| 乳清蛋白降血糖作用研究进展;徐庆等;《中国食物与营养》;20080831(第8期);第64页左栏最后1段 * |
| 亚麻籽的保健功能和开发利用;赵利等;《中国油脂》;20060331;第31卷(第3期);第72页右栏第4段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105231462A (en) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105231462B (en) | Compound antihypelipidemic nutrient powder | |
| Efird et al. | Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes | |
| CN105249466B (en) | Hypoglycemic food composition | |
| JP6013712B2 (en) | Biometabolic parameter improving agent comprising D-psicose as an active ingredient | |
| WO2018145664A1 (en) | Anti-fatigue composition for use in improving endurance performance | |
| JP6440843B2 (en) | Use of a composition comprising a ferrous amino acid chelate for the manufacture of a medicament for the regulation of fat metabolism | |
| JP2011116666A (en) | Anti-stress agent containing lactic bacterium-fermented royal jelly and method for producing the same | |
| WO2016141775A1 (en) | Uses of jilin ginseng oligopeptide in preparing food product or healthcare food product for combating fatigue | |
| CN109349490A (en) | A kind of solid drinks and preparation method thereof with the sugared function of polysaccharide of control | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| CN106573034B (en) | Marine peptides and fish nucleotides, compositions and uses thereof for lowering blood glucose | |
| Al-Aqaby et al. | Effectiveness of using probiotic Batcinel-K® and CEVAC SET-K® vaccine on some blood parameters in chickens | |
| TWI676473B (en) | Uses of poria cocos epidermis extract, poricoic acid a, and poricoic acid b in regulating blood glucose level | |
| JP2014505071A (en) | Plant extract preparation process | |
| CN102334525B (en) | Health-care food for reducing blood sugar | |
| KR101487245B1 (en) | Yakgwa comprising red ginseng and Preparation method thereof | |
| CN110754666A (en) | Protein solid preparation and preparation method thereof | |
| CN103250948A (en) | Series health food for diabetics with soybean meal and jerusalem artichoke as raw materials | |
| KR100679698B1 (en) | An extract of Pterocarya paliurus with blood sugar level-lowering activity and functional food comprising the same | |
| CN105167100A (en) | Crocodile polypeptide powder solid beverage composition facilitating postnatal postpartum recovery and preparation method of crocodile polypeptide powder solid beverage composition | |
| Yuguda | Profiling and In vivo studies of Bromelain Bitter Gourd (Momodica charantia) seed protein hydrolysate with antidiabetic activity | |
| Al-Rawashdeh et al. | The clinical impacts of early trophic feeding using protein formulas in compared with standard formulas in intolerated enteral nutrition hospitalized patients | |
| JP5870181B1 (en) | Serum cholesterol level and / or blood lipid level improver | |
| CN105106961B (en) | Composition, production method and application containing beer yeast extract | |
| Dashtabi et al. | Effects of dietary advanced glycation end-products restriction on renal function in patients with diabetic nephropathy; a randomized, double-blind clinical trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |